KAYEXALATE
What it isSodium polystyrene sulfonate, a cation exchange resin; hyperkalemia.
Why this oneUnlike newer potassium binders, its effect is poorly predictable and supported by weak evidence.
What limits itIt acts too slowly for emergencies, and sorbitol co-formulation has caused fatal colonic necrosis.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hyperkalemia (oral) | Adults | 15 g (60 mL) QD | 15 g (60 mL) 1–4×/day | 60 g/day |
| Hyperkalemia (rectal enema) | Adults | 30–50 g q6h | 30–50 g q6h | — |
| Hyperkalemia | Children/infants | Dose based on 1 mEq potassium per gram of resin | — | — |
Renal Undefined
Hepatic Undefined
Pregnancy Animal reproduction studies not conducted; use only if clearly needed
Lactation Undefined
NO BOXED WARNINGS
Principal riskColonic necrosis with sorbitol; slow and poorly effective
Cost, est. cash$5–$500/month
Generic entry1982
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.

Open Sodium polystyrene sulfonate in the interactive console ↗

Open Sodium polystyrene sulfonate in the interactive console ↗